First In Human Study of CX-2051 in Advanced Solid Tumors
← catalyst calendarNCT06265688 · readout in 467 d
Sponsored by CytomX Therapeutics (industry) · CTMX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
160estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-02 | actual | When the study began enrolling |
| Primary completion | 2027-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor, Adult
Interventions
- Drug: CX-2051
- Drug: Bevacizumab — also filed as Avastin
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of CX-2051
measured 44 months
Determine the recommended Phase 2 dose (RP2D)
measured 44 months
Permalink · CTMX's whole pipeline · Catalyst calendar · Every registered study · What changed